NSAIDs and cardiovascular health

被引：0
作者：
Gibofsky, Allan
Simon, Lee S.
White, William B.
机构：
来源：
POSTGRADUATE MEDICINE | 2006年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Reexamination of clinical studies and data from new clinical studies provided evidence that some cyclooxygenase (COX)-2 selective inhibitors may have additional cardiovascular (CV) risks associated with them. These additional risks are not shared by all of the new drugs, and individual patient risk factors must be considered in prescribing them for patients. Recent US Food and Drug Administration (FDA) recommendations for withdrawal of 2 of these drugs have raised questions for patients and physicians about use of the medications. Answers to these questions will determine how patients will use these drugs, and definitive answers will come from additional clinical studies.
引用
收藏
页码：28 / 44
页数：17
相关论文
共 43 条
[11]  
*FOOD DRUG ADM CTR, 2005, AL HEALHTC PROFESS V
[12]   Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study [J].
Graham, DJ ;
Campen, D ;
Hui, R ;
Spence, M ;
Cheetham, C ;
Levy, G ;
Shoor, S ;
Graham, D .
LANCET, 2005, 365 (9458) :475-481
[13]   Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis [J].
Hippisley-Cox, J ;
Coupland, C .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7504) :1366-1369
[14]   Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs -: A population-based case-control study [J].
Johnsen, SP ;
Larsson, H ;
Tarone, RE ;
McLaughlin, JK ;
Norgård, B ;
Friis, S ;
Sorensen, HT .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (09) :978-984
[15]   Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial [J].
Julius, S ;
Kjeldsen, SE ;
Weber, M ;
Brunner, HR ;
Ekman, S ;
Hansson, L ;
Hua, TS ;
Laragh, J ;
McInnes, GT ;
Mitchell, L ;
Plat, F ;
Schork, A ;
Smith, B ;
Zanchetti, A .
LANCET, 2004, 363 (9426) :2022-2031
[16]   Risk of cardiovascular events and rofecoxib: cumulative meta-analysis [J].
Juni, P ;
Nartey, L ;
Reichenbach, S ;
Sterchi, R ;
Dieppe, PA ;
Egger, M .
LANCET, 2004, 364 (9450) :2021-2029
[17]  
KIMMEL, 2002, CIRCULATION, V180
[18]   Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction [J].
Kimmel, SE ;
Berlin, JA ;
Reilly, M ;
Jaskowiak, J ;
Kishel, L ;
Chittams, J ;
Strom, BL .
ANNALS OF INTERNAL MEDICINE, 2005, 142 (03) :157-164
[19]   Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib [J].
Konstam, MA ;
Weir, MR ;
Reicin, A ;
Shapiro, D ;
Sperling, RS ;
Barr, E ;
Gertz, BJ .
CIRCULATION, 2001, 104 (19) :2280-2288
[20]   The risk for myocardial infarction with cyclooxygenase-2 inhibitors:: A population study of elderly adults [J].
Lévesque, LE ;
Brophy, JM ;
Zhang, B .
ANNALS OF INTERNAL MEDICINE, 2005, 142 (07) :481-489
12345